Strong U.S. Trade Policy Fuels American Leadership in Biopharmaceutical Innovation and Manufacturing

The innovative biopharmaceutical industry is a critical economic sector that contributes significantly to U.S. manufacturing and provides high-tech, high-skilled American jobs. U.S. companies and their employees lead the world in medical research, producing more than half of the world's new medicines in the last decade.

The biopharmaceutical industry is a key driver of the American economy:

$1.7 Trillion
in economic impact

$101 Billion
in exports

5 Million
U.S. jobs

1,500+
manufacturing facilities across 48 states and Puerto Rico

Industry-funded clinical trials touch patients in every state:

50%
of all U.S. investment in health and biomedical R&D

5,300
clinical trials for innovative medicines

Most innovative medicines taken in America are made in America:

53%
of active pharmaceutical ingredients (API) used in U.S.-consumed innovative medicines are produced in the United States

Nearly
2/3
of medicines, calculated by value, taken by U.S. patients are produced in the United States

85%
of imports of innovative medicines and inputs are sourced from Europe, Australia, Japan, Singapore and South Korea

The biopharmaceutical industry's large U.S. footprint depends on the ability to export American-made medicines to patients across the globe. U.S. trade policies that protect American IP rights internationally and eliminate foreign trade barriers are critical to the success of this vital American industry.

Learn more at PhRMA.org

PhRMA
RESEARCH • PROGRESS • HOPE